Metabolic Liver Disease and Obesity at a Therapeutic Crossroads: From Lifestyle Interventions to Incretin-based Pharmacotherapy

In this issue of the Journal of Atherosclerosis Prevention and Treatment, we bring together timely and complementary reviews that address the escalating burden of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), examining both emerging pharmacological therapies and long-term dietary strategies for cardiometabolic risk reduction. MASLD and obesity represent two tightly interwoven epidemics that increasingly define the global cardiometabolic burden. Their convergence is neither coincidental nor benign. Current epidemiologic evidence suggests that MASLD is now the leading cause of chronic liver disease worldwide, whereas obesity continues to rise at an alarming pace, with projections indicating that more than half of the global population will be living with excess body mass within the next decade. The articles presented in this issue address these challenges from complementary perspectives, i.e., pharmacological innovation and dietary strategy, offering timely insights into how metabolic disease management is evolving. The review by Blathra and Liberopoulos provides a comprehensive synthesis of emerging evidence supporting tirzepatide, a dual glucose-dependent insulinotropic polypeptide, and glucagon-like peptide-1 receptor agonist, as a promising therapeutic option for MASLD and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH). What distinguishes tirzepatide from earlier incretin-based therapies is not merely the magnitude of weight loss it induces, but the consistency with which improvements in hepatic outcomes have been observed across histological, imaging, and biomarker-based endpoints. Data from the SYNERGY-NASH trial represent a pivotal advance. Histological resolution of MASH without fibrosis worsening, long considered an elusive endpoint, was achieved in a dose-dependent manner, with rates exceeding 60% at the highest tirzepatide dose. These findings place tirzepatide among a small group of agents demonstrating meaningful disease modification rather than symptomatic or surrogate improvement alone. Importantly, fibrosis improvement without MASH progression was also observed in a substantial proportion of treated patients, addressing a key determinant of long-term liver-related outcomes. Imaging data from SURPASS-3 magnetic resonance imaging further reinforce these findings, showing marked reductions in liver fat content that correlated strongly with reductions in visceral adiposity and body weight. While weight loss is undeniably a central driver of MASLD improvement, mechanistic data summarized in the review suggest that tirzepatide exerts hepatic benefits that extend beyond caloric deficit. These include reduced hepatic lipid uptake, modulation of de novo lipogenesis, improved insulin sensitivity, and favorable effects on adipokine profiles and inflammatory pathways. Collectively, these data signal a paradigm shift: MASLD pharmacotherapy is transitioning from repurposed metabolic agents toward targeted, disease-modifying treatments. However, several questions remain unresolved. Long-term safety beyond 1–2 years, durability of histological response, cost-effectiveness, and real-world applicability in populations with advanced fibrosis or multimorbidity require further clarification. Moreover, how tirzepatide should be positioned relative to emerging liver-directed agents, such as thyroid hormone receptor-β agonists, remains an open clinical question, as highlighted by the authors. In parallel, the systematic review by Vlastaridou et al. addresses a fundamentally different but equally important aspect of metabolic disease management: the long-term effectiveness of intermittent fasting as a dietary strategy for weight loss and metabolic risk reduction. While intermittent fasting has gained substantial popularity, robust evidence extending beyond short-term interventions has been limited. This review, therefore, fills a critical gap by focusing exclusively on randomized controlled trials of at least 12-month duration. The authors suggest that intermittent fasting is broadly comparable to continuous energy restriction (CER) for long-term weight management, challenging the notion that fasting-based approaches are inherently superior. Among the various intermittent fasting regimens, alternate-day modified fasting (ADMF) emerged as the only strategy demonstrating consistently greater weight loss than CER. Time-restricted eating, particularly when combined with caloric restriction, appeared more effective in reducing fat mass, although overall weight loss remained similar to conventional approaches. From a metabolic standpoint, intermittent fasting regimens, especially ADMF, showed modest advantages in improving insulin sensitivity, reflected by greater reductions in fasting insulin and Homeostatic Model Assessment of Insulin Resistance. However, these benefits were accompanied by less favorable lipid changes in some studies, including higher total and Low Density Lipoprotein (LDL) cholesterol compared with CER. These findings underscore the metabolic trade-offs inherent in dietary interventions and caution against overly simplistic narratives portraying IF as universally beneficial. The most important contribution of this review lies in its emphasis on adherence and sustainability. Long-term success in obesity management depends less on the theoretical superiority of a dietary pattern and more on its acceptability, flexibility, and alignment with individual lifestyles and biological rhythms. The heterogeneity of responses observed across intermittent fasting regimens reinforces the need for personalized nutritional strategies rather than prescriptive, one-size-fits-all solutions. Taken together, a critical evolution in metabolic disease management is highlighted; lifestyle interventions and pharmacological therapies should no longer be viewed as competing paradigms but as complementary tools. Weight loss remains a cornerstone of MASLD treatment, whether achieved through dietary modification, pharmacotherapy, or their combination. However, the magnitude and durability of weight loss required to reverse advanced liver disease may be unattainable for many patients through lifestyle measures alone. In this context, agents such as tirzepatide may serve as powerful enablers of lifestyle change, facilitating adherence and amplifying metabolic benefits. Conversely, dietary strategies, including intermittent fasting, may enhance or sustain pharmacologically induced weight loss and metabolic improvements, particularly when tailored to individual circadian, behavioral, and metabolic profiles. The future of obesity and MASLD management lies in precision medicine. This entails identifying which patients are most likely to benefit from specific dietary patterns, pharmacological agents, or their combination, based on genetic predisposition, metabolic phenotype, disease stage, and patient preference. It also requires moving beyond surrogate endpoints toward hard clinical outcomes, including liver-related events, cardiovascular disease, and mortality. This issue underscores not only that the therapeutic landscape is rapidly expanding but also that thoughtful integration of evidence is essential. As incretin-based therapies redefine what is achievable pharmacologically, and as dietary strategies evolve toward greater personalization, clinicians and researchers must remain vigilant in balancing efficacy, safety, sustainability, and equity.